DBV submits FDA BLA for VIASKIN Peanut Patch in children ages 4-7
Bitget2026/09/29 22:29- DBV Technologies submitted a BLA to the FDA for its VIASKIN Peanut Patch in children aged 4-7 years.
- The filing seeks Priority Review. The FDA previously granted Breakthrough Therapy designation for the product.
- Application backed by Phase 3 VITESSE data in 654 children, described as the largest immunotherapy trial in this population.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Fixed income stalls and stocks take the crown! Wall Street’s big banks report an epic “song of ice and fire” season, marking the darkest hour for a generation of bond traders
As Wall Street's fixed income division came under pressure in the third quarter, its equities division competitors seized this rare opportunity, overshadowing their peers in the fixed income sector.
Rio Tinto on track to release $5 billion in capital after Q3 iron ore sales top estimates
Glencore shares to start trading in Australia as miner hopes to boost valuation
How will the market perform during the remainder of 2026?
Crypto prices
More
